Psychedelics Co. Pasithea Therapeutics Prices $24M IPO At $5 Per Share

Pasithea Therapeutics, a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, filed its registration statement on Form S-1 for a proposed  $24.0 million IPO.

What Happened

On Wednesday, the company announced the pricing of its initial public offering of 4.8 million units, with each unit consisting of one share of common stock, at a public offering price of $5.00 per Unit.

Why It Matters

“Today’s announcement is a monumental achievement for Pasithea. Our successful IPO is testament to our work as a biotech company paving the way for new solutions to address how we treat disorders,” Dr. Tiago Reis Marques, CEO and director of Pasithea Therapeutics Corp told …

Full story available on Benzinga.com

More Psychedelics Co. Pasithea Therapeutics Prices $24M IPO At $5 Per Share